![Oncotarget](https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png)
Oncotarget | Site of Analysis Matters – Ongoing Complete Response to Nivolumab in Patient With HIV/HPV Related Metastatic Anal Cancer and MLH1 Mutation
September 29, 2022
This case report represents an HIV infected patient with anal cancer, MSI high status, a high mutation frequency regarding tumor mutational burden (TMB), and an ongoing response to Nivolumab.”BUFFALO,... read more